Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer

INTRODUCTION: Cyclin-dependent kinase (CDK)4/6 inhibitor is a first-line therapy for metastatic ER+/HER2-breast cancer. However, there are limited data on safety of combined radiotherapy (RT) and CDK4/6 inhibition. METHODS: We conducted a retrospective study of women with metastatic breast cancer wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kristine N., Shah, Payal, Clark, Amy, Freedman, Gary M., Dastgheyb, Sana, Barsky, Andrew R., Dreyfuss, Alexandra D., Taunk, Neil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527028/
https://www.ncbi.nlm.nih.gov/pubmed/34653725
http://dx.doi.org/10.1016/j.breast.2021.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527028/
https://www.ncbi.nlm.nih.gov/pubmed/34653725
http://dx.doi.org/10.1016/j.breast.2021.10.001

Ejemplares similares